Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 50

1.

Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children.

Brandao LR, Albisetti M, Halton J, Bomgaars L, Chalmers E, Mitchell LG, Nurmeev I, Svirin P, Kuhn T, Zapletal O, Tartakovsky I, Simetzberger M, Huang F, Sun Z, Kreuzer J, Gropper S, Brueckmann M, Luciani M.

Blood. 2019 Dec 5. pii: blood.2019000998. doi: 10.1182/blood.2019000998. [Epub ahead of print]

2.

The Population Pharmacokinetics of High-Dose Methotrexate in Infants with Acute Lymphoblastic Leukemia Highlight the Need for Bedside Individualized Dose Adjustment: A Report from the Children's Oncology Group.

Beechinor RJ, Thompson PA, Hwang MF, Vargo RC, Bomgaars LR, Gerhart JG, Dreyer ZE, Gonzalez D.

Clin Pharmacokinet. 2019 Jul;58(7):899-910. doi: 10.1007/s40262-018-00734-0.

PMID:
30810947
3.

Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.

Hawkins DS, Chi YY, Anderson JR, Tian J, Arndt CAS, Bomgaars L, Donaldson SS, Hayes-Jordan A, Mascarenhas L, McCarville MB, McCune JS, McCowage G, Million L, Morris CD, Parham DM, Rodeberg DA, Rudzinski ER, Shnorhavorian M, Spunt SL, Skapek SX, Teot LA, Wolden S, Yock TI, Meyer WH.

J Clin Oncol. 2018 Sep 20;36(27):2770-2777. doi: 10.1200/JCO.2018.77.9694. Epub 2018 Aug 9.

4.

Phase 3, single-arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design.

Luciani M, Albisetti M, Biss B, Bomgaars L, Brueckmann M, Chalmers E, Gropper S, Halton JML, Harper R, Huang F, Manastirski I, Mitchell LG, Tartakovsky I, Wang B, Brandão LR.

Res Pract Thromb Haemost. 2018 Apr 24;2(3):580-590. doi: 10.1002/rth2.12093. eCollection 2018 Jul.

5.

Design and rationale for the DIVERSITY study: An open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolism.

Albisetti M, Biss B, Bomgaars L, Brandão LR, Brueckmann M, Chalmers E, Gropper S, Harper R, Huang F, Luciani M, Manastirski I, Mitchell LG, Tartakovsky I, Wang B, Halton JML.

Res Pract Thromb Haemost. 2018 Mar 25;2(2):347-356. doi: 10.1002/rth2.12086. eCollection 2018 Apr.

6.

Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability.

Halton JML, Albisetti M, Biss B, Bomgaars L, Brueckmann M, Gropper S, Harper R, Huang F, Luciani M, Maas H, Tartakovsky I, Mitchell LG.

J Thromb Haemost. 2017 Nov;15(11):2147-2157. doi: 10.1111/jth.13847. Epub 2017 Oct 26.

7.

Antithrombotic Therapy in a Prospective Trial of a Pediatric Ventricular Assist Device.

Steiner ME, Bomgaars LR, Massicotte MP; Berlin Heart EXCOR Pediatric VAD IDE study investigators.

ASAIO J. 2016 Nov/Dec;62(6):719-727.

8.

Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward.

Lagmay JP, Krailo MD, Dang H, Kim A, Hawkins DS, Beaty O 3rd, Widemann BC, Zwerdling T, Bomgaars L, Langevin AM, Grier HE, Weigel B, Blaney SM, Gorlick R, Janeway KA.

J Clin Oncol. 2016 Sep 1;34(25):3031-8. doi: 10.1200/JCO.2015.65.5381. Epub 2016 Jul 11.

9.

Efficacy and safety of protein C concentrate to treat purpura fulminans and thromboembolic events in severe congenital protein C deficiency.

Manco-Johnson MJ, Bomgaars L, Palascak J, Shapiro A, Geil J, Fritsch S, Pavlova BG, Gelmont D.

Thromb Haemost. 2016 Jul 4;116(1):58-68. doi: 10.1160/TH15-10-0786. Epub 2016 Apr 7.

PMID:
27052576
10.

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.

Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kühne T, Jürgens H, van den Berg H, Böhling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M; EURAMOS-1 investigators.

J Clin Oncol. 2015 Jul 10;33(20):2279-87. doi: 10.1200/JCO.2014.60.0734. Epub 2015 Jun 1. Erratum in: J Clin Oncol. 2016 Nov 20;34(33):4059.

11.

Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation.

Hundalani SG, Nguyen KT, Soundar E, Kostousov V, Bomgaars L, Moise A, Hui SK, Teruya J.

Pediatr Crit Care Med. 2014 Jun;15(5):e198-205. doi: 10.1097/PCC.0000000000000107.

PMID:
24614609
12.

Response to warfarin therapy in obese pediatric patients dosed according to institutional guidelines.

Moffett BS, Bomgaars LR.

J Pediatr Hematol Oncol. 2014 Nov;36(8):e487-9. doi: 10.1097/MPH.0000000000000087.

PMID:
24458250
13.

Anticoagulation therapy trends in children supported by ventricular assist devices: a multi-institutional study.

Moffett BS, Cabrera AG, Teruya J, Bomgaars L.

ASAIO J. 2014 Mar-Apr;60(2):211-5. doi: 10.1097/MAT.0000000000000037.

PMID:
24399058
14.

Readmissions for warfarin-related bleeding in pediatric patients after hospital discharge.

Moffett BS, Kim S, Bomgaars LR.

Pediatr Blood Cancer. 2013 Sep;60(9):1503-6. doi: 10.1002/pbc.24546. Epub 2013 Apr 20.

PMID:
23606286
15.

Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin.

Richard AA, Kim S, Moffett BS, Bomgaars L, Mahoney D Jr, Yee DL.

J Pediatr. 2013 Feb;162(2):293-6. doi: 10.1016/j.jpeds.2012.07.047. Epub 2012 Sep 5.

PMID:
22959138
16.

Prospective trial of a pediatric ventricular assist device.

Fraser CD Jr, Jaquiss RD, Rosenthal DN, Humpl T, Canter CE, Blackstone EH, Naftel DC, Ichord RN, Bomgaars L, Tweddell JS, Massicotte MP, Turrentine MW, Cohen GA, Devaney EJ, Pearce FB, Carberry KE, Kroslowitz R, Almond CS; Berlin Heart Study Investigators.

N Engl J Med. 2012 Aug 9;367(6):532-41. doi: 10.1056/NEJMoa1014164.

17.

Risk factors for elevated INR values during warfarin therapy in hospitalized pediatric patients.

Moffett BS, Ung M, Bomgaars L.

Pediatr Blood Cancer. 2012 Jun;58(6):941-4. doi: 10.1002/pbc.23308. Epub 2011 Nov 8.

PMID:
22069087
18.

Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP).

Klaassen RJ, Mathias SD, Buchanan G, Bussel J, Deuson R, Young NL, Collier A, Bomgaars L, Blanchette V.

Pediatr Blood Cancer. 2012 Mar;58(3):395-8. doi: 10.1002/pbc.23312. Epub 2011 Sep 9.

PMID:
21910213
19.

A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia.

Bussel JB, Buchanan GR, Nugent DJ, Gnarra DJ, Bomgaars LR, Blanchette VS, Wang YM, Nie K, Jun S.

Blood. 2011 Jul 7;118(1):28-36. doi: 10.1182/blood-2010-10-313908. Epub 2011 Apr 18.

PMID:
21502541
20.

Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.

Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada H, Sandler A, Shamberger RC, Look AT, Reynolds CP, Seeger RC, Matthay KK; Children’s Oncology Group.

N Engl J Med. 2010 Sep 30;363(14):1313-23. doi: 10.1056/NEJMoa1001527.

Supplemental Content

Loading ...
Support Center